Elyana Locatelli, BS, is a pre-medical student and research fellow at University of Miami’s Bascom Palmer Eye Institute under the guidance of Dr. Anat Galor.
This abstract was presented as a poster at the 2023 ARVO annual meeting, held in New Orleans, USA, April 23-27, 2023. (Download poster .pdf)
Abstract Number: 3952 – B0269
Authors: Elyana V. Locatelli1,2, Kelly Acuna1,2, Arianna Tovar2, Jason Betz2, Anat Galor1,2
1Ophthalmology, VA Miami Healthcare System, Miami, FL, United States,2Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, FL, United States.
Commercial Relationship Disclosure: Elyana Locatelli: None, Kelly Acuna: None, Arianna Tovar: None, Jason Betz: None, Anat Galor: None.
Purpose
To examine subjective response to cyclosporine A (CsA) 0.05% versus lifitegrast 5% in individuals with dry eye disease (DED).
Methods
Retrospective review of individuals with clinically diagnosed DED treated with both CsA 0.05% and lifitegrast 5% over the course of their disease. Information collected included demographics, co-morbidities, and DED signs. Treatment preferences were noted as mild or strong for a particular medication, no preference, or unable to tolerate either medication. The primary outcome measure was patient-reported medication preference. The secondary outcome measure was an examination of individual and eye factors that related to medication preference.
Results
64 individuals (mean age 66.73±13.17 years; 82.8% male, 71.9% White, 29.7% Hispanic) used both CsA and lifitegrast over the course of their disease. Of those, 33 preferred CsA (12.5% mildly, 39.1% strongly); 14 preferred lifitegrast (3.1% mildly, 18.8% strongly); 12 had no preference (18.8%); and 5 could not tolerate either medication (7.8%) due to side effects. No demographic characteristics, co-morbidities, or ocular surface findings correlated with medication preference.
Conclusions
In individuals who used both CsA 0.05% and lifitegrast 5% over the course of their disease, a higher frequency of individuals preferred CsA. No clinical factors correlated with medication preference.
